These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 29483621)
1. The efficacy of Ranolazine on E1784K is altered by temperature and calcium. Abdelsayed M; Ruprai M; Ruben PC Sci Rep; 2018 Feb; 8(1):3643. PubMed ID: 29483621 [TBL] [Abstract][Full Text] [Related]
2. Differential calcium sensitivity in Na Abdelsayed M; Baruteau AE; Gibbs K; Sanatani S; Krahn AD; Probst V; Ruben PC J Physiol; 2017 Sep; 595(18):6165-6186. PubMed ID: 28734073 [TBL] [Abstract][Full Text] [Related]
3. Further Insights in the Most Common SCN5A Mutation Causing Overlapping Phenotype of Long QT Syndrome, Brugada Syndrome, and Conduction Defect. Veltmann C; Barajas-Martinez H; Wolpert C; Borggrefe M; Schimpf R; Pfeiffer R; Cáceres G; Burashnikov E; Antzelevitch C; Hu D J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27381756 [TBL] [Abstract][Full Text] [Related]
4. Differential thermosensitivity in mixed syndrome cardiac sodium channel mutants. Abdelsayed M; Peters CH; Ruben PC J Physiol; 2015 Sep; 593(18):4201-23. PubMed ID: 26131924 [TBL] [Abstract][Full Text] [Related]
5. E1784K, the most common Brugada syndrome and long-QT syndrome type 3 mutant, disrupts sodium channel inactivation through two separate mechanisms. Peters CH; Watkins AR; Poirier OL; Ruben PC J Gen Physiol; 2020 Sep; 152(9):. PubMed ID: 32569350 [TBL] [Abstract][Full Text] [Related]
6. Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients. Hu RM; Tester DJ; Li R; Sun T; Peterson BZ; Ackerman MJ; Makielski JC; Tan BH Channels (Austin); 2018; 12(1):176-186. PubMed ID: 29983085 [TBL] [Abstract][Full Text] [Related]
7. A heterozygous deletion mutation in the cardiac sodium channel gene SCN5A with loss- and gain-of-function characteristics manifests as isolated conduction disease, without signs of Brugada or long QT syndrome. Zumhagen S; Veldkamp MW; Stallmeyer B; Baartscheer A; Eckardt L; Paul M; Remme CA; Bhuiyan ZA; Bezzina CR; Schulze-Bahr E PLoS One; 2013; 8(6):e67963. PubMed ID: 23840796 [TBL] [Abstract][Full Text] [Related]
8. Eleclazine exhibits enhanced selectivity for long QT syndrome type 3-associated late Na El-Bizri N; Xie C; Liu L; Limberis J; Krause M; Hirakawa R; Nguyen S; Tabuena DR; Belardinelli L; Kahlig KM Heart Rhythm; 2018 Feb; 15(2):277-286. PubMed ID: 29017927 [TBL] [Abstract][Full Text] [Related]
9. Complex interactions in a novel SCN5A compound mutation associated with long QT and Brugada syndrome: Implications for Na+ channel blocking pharmacotherapy for de novo conduction disease. Liu J; Bayer JD; Aschar-Sobbi R; Wauchop M; Spears D; Gollob M; Vigmond EJ; Tsushima R; Backx PH; Chauhan VS PLoS One; 2018; 13(5):e0197273. PubMed ID: 29791480 [TBL] [Abstract][Full Text] [Related]
10. Structure of human Na Li Z; Jin X; Wu T; Zhao X; Wang W; Lei J; Pan X; Yan N Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33712541 [TBL] [Abstract][Full Text] [Related]
11. A distinct molecular mechanism by which phenytoin rescues a novel long QT 3 variant. Gando I; Campana C; Tan RB; Cecchin F; Sobie EA; Coetzee WA J Mol Cell Cardiol; 2020 Jul; 144():1-11. PubMed ID: 32339567 [TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of chronic mexiletine treatment in a human model of SCN5A overlap syndrome. Nasilli G; Yiangou L; Palandri C; Cerbai E; Davis RP; Verkerk AO; Casini S; Remme CA Europace; 2023 Jun; 25(6):. PubMed ID: 37369559 [TBL] [Abstract][Full Text] [Related]
13. Systematic ajmaline challenge in patients with long QT 3 syndrome caused by the most common mutation: a multicentre study. Hohmann S; Rudic B; Konrad T; Duncker D; König T; Tülümen E; Rostock T; Borggrefe M; Veltmann C Europace; 2017 Oct; 19(10):1723-1729. PubMed ID: 27915266 [TBL] [Abstract][Full Text] [Related]
14. Tbx5 variants disrupt Nav1.5 function differently in patients diagnosed with Brugada or Long QT Syndrome. Nieto-Marín P; Tinaquero D; Utrilla RG; Cebrián J; González-Guerra A; Crespo-García T; Cámara-Checa A; Rubio-Alarcón M; Dago M; Alfayate S; Filgueiras-Rama D; Peinado R; López-Sendón JL; Jalife J; Tamargo J; Bernal JA; Caballero R; Delpón E; Cardiovasc Res; 2022 Mar; 118(4):1046-1060. PubMed ID: 33576403 [TBL] [Abstract][Full Text] [Related]
15. Lidocaine attenuation testing: An in vivo investigation of putative LQT3-associated variants in the SCN5A-encoded sodium channel. Anderson HN; Bos JM; Kapplinger JD; Meskill JM; Ye D; Ackerman MJ Heart Rhythm; 2017 Aug; 14(8):1173-1179. PubMed ID: 28412158 [TBL] [Abstract][Full Text] [Related]
16. Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data. Chorin E; Hu D; Antzelevitch C; Hochstadt A; Belardinelli L; Zeltser D; Barajas-Martinez H; Rozovski U; Rosso R; Adler A; Benhorin J; Viskin S Circ Arrhythm Electrophysiol; 2016 Oct; 9(10):. PubMed ID: 27733495 [TBL] [Abstract][Full Text] [Related]
17. Voltage-Gated Sodium Channel Phosphorylation at Ser571 Regulates Late Current, Arrhythmia, and Cardiac Function In Vivo. Glynn P; Musa H; Wu X; Unudurthi SD; Little S; Qian L; Wright PJ; Radwanski PB; Gyorke S; Mohler PJ; Hund TJ Circulation; 2015 Aug; 132(7):567-77. PubMed ID: 26187182 [TBL] [Abstract][Full Text] [Related]
19. The Citrus Flavonoid Hesperetin Has an Inadequate Anti-Arrhythmic Profile in the ΔKPQ Na Alvarez-Collazo J; López-Requena A; Alvarez JL; Talavera K Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32599724 [TBL] [Abstract][Full Text] [Related]
20. Modeling incomplete penetrance in long QT syndrome type 3 through ion channel heterogeneity: an in silico population study. Miller JA; Moise N; Weinberg SH Am J Physiol Heart Circ Physiol; 2023 Feb; 324(2):H179-H197. PubMed ID: 36487185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]